Barclays PLC Acquires 120,789 Shares of Annexon, Inc. (NASDAQ:ANNX)

Barclays PLC raised its stake in Annexon, Inc. (NASDAQ:ANNX) by 212.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 177,765 shares of the company’s stock after buying an additional 120,789 shares during the quarter. Barclays PLC owned about 0.17% of Annexon worth $1,052,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sandia Investment Management LP acquired a new stake in shares of Annexon during the second quarter worth $49,000. Victory Capital Management Inc. acquired a new stake in shares of Annexon in the 2nd quarter valued at about $51,000. Principal Financial Group Inc. bought a new stake in shares of Annexon in the second quarter valued at about $56,000. Quarry LP acquired a new position in shares of Annexon during the third quarter worth about $118,000. Finally, Intech Investment Management LLC bought a new position in shares of Annexon during the third quarter worth about $154,000.

Annexon Trading Down 8.3 %

NASDAQ ANNX opened at $4.53 on Wednesday. The firm has a market capitalization of $482.87 million, a P/E ratio of -4.31 and a beta of 1.11. The firm’s fifty day moving average price is $5.37 and its two-hundred day moving average price is $5.95. Annexon, Inc. has a 1 year low of $3.86 and a 1 year high of $8.40.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Annexon in a research report on Tuesday, December 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Annexon in a research report on Friday, November 15th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Annexon has a consensus rating of “Buy” and an average price target of $15.80.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.